The early days of the US International Development Finance Corporation (DFC) have been defined by a mixed record, and its health-focused investments are no exception. In the face of competing foreign (and even domestic) policy priorities under the Trump Administration and pandemic-related shifts in the broader development landscape, the agency has struggled to build a solid pipeline of projects in lower-income markets and systematically articulate a strong development rationale for its financing.
CGD Policy Blogs
DFIs are well positioned to address five pressure points in the COVID-19 response that need financing. Let’s unpack these one by one.
From Vision to Architecture: Three Questions to Guide the Global Family Planning Movement Towards 2030
The start of 2020 marks a critical juncture for Family Planning 2020. Authors explore the Beyond 2020 Vision and pose three central questions for the Core Partners and family planning community to consider.
Effective procurement of health products—medicines, diagnostics, and devices—is a foundational function for any health system and essential for progress toward the health-related Sustainable Development Goals.
To achieve universal health coverage and provide their citizens with access to quality and affordable medicines, countries will need to buy these lifesaving products efficiently and effectively.
Health products—including drugs, devices, diagnostics, and vector control tools—are essential for meeting the healthcare needs of any population. Right now, many low- and lower-middle-income countries rely on donor-managed mechanisms to procure a large share of these health commodities. But this status quo won’t stay static for long, and the global health community must prepare for sweeping changes in global health and procurement over the next 10–20 years. Here’s some of what we see happening now and on the immediate horizon.